Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23723763 | 0.80 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL3399693 | 0.80 | DGAT1 (0.41) | DGAT1 | |
| SCHEMBL3406112 | 0.79 | DGAT1 (0.39) | DGAT1 | |
| SCHEMBL3405434 | 0.77 | DGAT1 (0.35) | DGAT1 | |
| SCHEMBL3405596 | 0.77 | DGAT1 (0.37) | DGAT1 | |
| SCHEMBL3403488 | 0.74 | DGAT1 (0.36) | DGAT1 | |
| SCHEMBL26136077 | 0.73 | DGAT1 (0.43) | DGAT1 | |
| SCHEMBL22759279 | 0.73 | DGAT1 (0.33) | DGAT1 | |
| SCHEMBL31503370 | 0.70 | DGAT1 (0.31) | DGAT1 | |
| SCHEMBL22412565 | 0.70 | KLKB1 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2040700-B1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LTD (GB) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009074519-A1 | COMBINATIONS OF PYRAZOLYL OR ISOXAZOLYL P2X7 MODULATORS WITH FURTHER THERAPEUTIC AGENTS | GLAXO GROUP LIMITED (GB) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | GLAXO GROUP LIMITED (GB) | 2009-06-11 | — | — | US | disclosed |
| EP-2040700-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | Glaxo Group Limited (GB) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007141267-A1 | N- (PHENYLMETHYL) -2- (1H-PYRAZ0L-4-YL) ACETAMIDE DERIVATIVES AS P2X7 ANTAGONISTS FOR THE TREATMENT OF PAIN, INFLAMMATION AND NEURODEGENERATION | GLAXO GROUP LIMITED (GB) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149524-A1 | N-(Phenylmethyl)-2-(1H-Pyrazol-4-yl) Acetamide Derivatives as P2X7 Antagonists for the Treatment of Pain, Inflammation and Neurodegeneration | P2RX3, P2RX7, P2RX1 | DGAT1 4506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.